Delving into the Latest Updates on GS-1427 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

GS 1427, GS-1427

Target

α4β7

Action

antagonists

Mechanism

α4β7 antagonists(Integrin alpha-4/beta-7 antagonists)

Therapeutic Areas

Immune System DiseasesDigestive System Disorders

Active Indication

Colitis, UlcerativeInflammatory Bowel Diseases

Inactive Indication-

Originator Organization

Gilead Sciences, Inc.

Active Organization

Gilead Sciences, Inc.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

The goal of this study is to learn if GS-1427 is effective in treating participants with moderate to severe ulcerative colitis. The study will compare participants in different treatment groups treated with GS-1427 with participants treated with placebo.
The primary objective of this study is to assess the efficacy of GS-1427, compared with placebo control, in achieving clinical response at Week 12.

Start Date27 Mar 2024

Sponsor / Collaborator

Gilead Sciences, Inc.

ACTRN12621000612819

/ CompletedPhase 1

A Phase 1, Dose-Escalation Study in Healthy Volunteers to Evaluate the Pharmacokinetics, Safety, and Tolerability of GS-1427 Following Single and Multiple Dosing

Start Date15 Jun 2021

Sponsor / Collaborator

Gilead Sciences, Inc.

100 Clinical Results associated with GS-1427

Login to view more data

100 Translational Medicine associated with GS-1427

Login to view more data

100 Patents (Medical) associated with GS-1427

Login to view more data

100 Deals associated with GS-1427

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Colitis, Ulcerative	Phase 2	United States	Gilead Sciences, Inc.	27 Mar 2024
Colitis, Ulcerative	Phase 2	Australia	Gilead Sciences, Inc.	27 Mar 2024
Colitis, Ulcerative	Phase 2	Austria	Gilead Sciences, Inc.	27 Mar 2024
Colitis, Ulcerative	Phase 2	Belgium	Gilead Sciences, Inc.	27 Mar 2024
Colitis, Ulcerative	Phase 2	Canada	Gilead Sciences, Inc.	27 Mar 2024
Colitis, Ulcerative	Phase 2	Czechia	Gilead Sciences, Inc.	27 Mar 2024
Colitis, Ulcerative	Phase 2	France	Gilead Sciences, Inc.	27 Mar 2024
Colitis, Ulcerative	Phase 2	Germany	Gilead Sciences, Inc.	27 Mar 2024
Colitis, Ulcerative	Phase 2	Hong Kong	Gilead Sciences, Inc.	27 Mar 2024
Colitis, Ulcerative	Phase 2	Hungary	Gilead Sciences, Inc.	27 Mar 2024